Browse drug registration pathways, regulators, CTD dossier expectations, review procedures, holder duties, and post-approval obligations by country.
Public pages show drug registration overviews; during the limited-time free period, sign in or register to view complete pathways.
Drug registration routes in the same region often share CTD structure, local holder, GMP/CPP, label-language, and post-approval patterns. Start with the regional pattern, then open the country page for differences.
Typical flow: local holder or agent, CTD/eCTD, CPP/GMP, label-language work, and pharmacovigilance setup. LATAM markets often require Spanish/Portuguese localization and may focus on BE or clinical bridging.
Typical flow: local MAH/agent, CTD or ASEAN CTD, GMP/CPP, samples/testing, and label-language checks. ASEAN markets share dossier logic; China, Japan, and Korea have heavier local clinical and administrative requirements.
Typical flow: EU CTD, centralized/MRP/DCP/national route, QP/PV system, SmPC/PIL, and local languages. UK, Switzerland, and other non-EU markets require separate holders and filing routes.
Typical flow: local agent or holder, CTD, CPP/GMP, legalization, Arabic labeling, and local pharmacovigilance contact. GCC markets can reference one another but still keep local submission and fee steps.
12 countries
Typical flow: local MAH/agent, CTD or ASEAN CTD, GMP/CPP, samples/testing, and label-language checks. ASEAN markets share dossier logic; China, Japan, and Korea have heavier local clinical and administrative requirements.
Market Overview Market profile: Australia has a transparent regulatory system. TGA registration and PBS reimbursement are separate but connected market access steps. Regulatory mat...
Updated: 2026-05-04
Market Overview Market profile: Drug registration in China is led by NMPA, with CDE conducting core technical review. Innovative drugs, modified new drugs, generics, biologics, and...
Updated: 2026-05-04
Market Overview Market profile: India is one of the world's largest pharmaceutical volume markets, a global hub for generics, vaccines, biosimilars, APIs, and contract manufacturin...
Updated: 2026-05-04
Market Overview Market profile: Indonesia has a large population base. Prescription drugs, generics, vaccines, halal expectations, and localisation policy all influence market entr...
Updated: 2026-05-04
Market Overview Market profile: Japan is a highvalue pharmaceutical market. PMDA review quality, NHI pricing, Japanese dossier materials, and local MAH structure are critical. Regu...
Updated: 2026-05-04
Market Overview Market profile: Malaysia has a clear regulatory system and supports layered entry for new drugs, generics, biologics, health supplements, and natural products. Regu...
Updated: 2026-05-04
Market Overview Market profile: The Philippines pharmaceutical market is driven by generics, prescription medicines, hospitals, and pharmacy channels. Product registration, LTO, an...
Updated: 2026-05-04
Market Overview Market profile: Singapore is a smaller market by volume, but it is highly transparent, Englishfriendly, and important for innovative drugs, generics, biosimilars, a...
Updated: 2026-05-04
Market Overview Market profile: South Korea has a mature pharmaceutical regulatory system with defined pathways for innovative drugs, biosimilars, and generics. Korean materials an...
Updated: 2026-05-04
Market Overview Market profile: Taiwan has a mature drug registration system. TFDA approval and National Health Insurance reimbursement are connected but separate access steps. Reg...
Updated: 2026-05-04
Market Overview Market profile: Thailand is a major Southeast Asian pharmaceutical market with public hospitals, private hospitals, and pharmacy channels. Registration, import lice...
Updated: 2026-05-04
Market Overview Market profile: Vietnam's pharmaceutical market is growing quickly. Hospital procurement, imported drugs, generics, local manufacturing, and reimbursement all shape...
Updated: 2026-05-04
